DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for ovarian angiosarcoma — screening already-approved drugs against its 7-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleOvarian angiosarcoma maps to a 7-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for ovarian angiosarcoma is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
RAD51 paralog B (RAD51B) — RAD51B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet adpdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 9Q2A · 2.67 Å · ligand ADENOSINE-5'-DIPHOSPHATE (ADP). Experimental structure, not a prediction.
What the evidence adds up to
Ovarian angiosarcoma is exceedingly rare; by 1994 only 15 cases had been described, and by 2011 the count had reached 31. All tumours have been highly aggressive. No response to any treatment had ever been reported until a single case in 1994 achieved a short remission with intensive ifosfamide and doxorubicin. More than half of ovarian angiosarcomas are disseminated at diagnosis; only a minority are stage I. The prognosis is poor overall. Most reports concern patients aged 7 to 46 years; only two cases had been found in patients older than 64 before an 81-year-old patient was described in 2011.
A 2019 case report states that the 5-year overall survival for nonmetastatic disease is less than 30%, and for metastatic disease death within one year is almost certain. That report describes an 11-year-old female with metastatic ovarian angiosarcoma who received systemic chemotherapy and cytoreductive surgery with heated intraperitoneal chemotherapy. She was alive and well three years after diagnosis, which the authors note is significantly longer than any reported case of advanced-stage disease. This is the second reported use of heated intraperitoneal chemotherapy for this tumour.
The evidence consists entirely of single case reports and small literature reviews. No prospective trial, no controlled comparison, and no consistent regimen have been tested. The 1994 remission with ifosfamide and doxorubicin was short. The 2019 long-term survivor is a single paediatric patient; it is not known whether the heated intraperitoneal chemotherapy, the systemic chemotherapy, or the surgery itself contributed to her outcome. What is still missing is any systematic trial, any funding for a multi-centre registry, and any way to stratify patients by tumour biology or stage before selecting therapy.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Gynecologic Oncology · 1994 · 39 citations · open access
Treatment of Primary Ovarian Angiosarcoma with Ifosfamide and Doxorubicin
AbstractAngiosarcoma originating in the female genital tract is exceedingly rare with only 15 cases of angiosarcoma of the ovary described to date. All have been highly aggressive tumors, and no response to treatment has ever been reported. A case of primary ovarian angiosarcoma is described in which a short remission was achieved with intensive chemotherapy using ifosfamide and doxorubicin.
Diagnostic Pathology · 2011 · 27 citations · open access
Primary angiosarcoma of the ovary with prominent fibrosis of the ovarian stroma. Case report of an 81-year old patient
AbstractPrimary angiosarcoma of the ovary (AS) is a rare entity with only 31 reported cases. The majority are pure angiosarcomas, the remainder are associated either with teratomas or conventional epithelial tumors. More than 50% of ovarian AS are disseminated at the time of diagnosis, the minority is detected in stage I. The prognosis of ovarian angiosarcoma in general is poor. Most reports refer to younger individuals, aged from 7 to 46 years, and only 2 case reports could be found for patients older than 64 years. Here we present a very unusual case of angiosarcoma in a 81-year-old patient. The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/3507343435434581 .
Pediatric ovarian angiosarcoma treated with systemic chemotherapy and cytoreductive surgery with heated intraperitoneal chemotherapy: Case report and review of therapy
AbstractOvarian angiosarcoma is a rare and aggressive vascular tumor, which has a 5-year overall survival of less than 30% for patients with nonmetastatic disease and almost certain death within 1 year for those with metastasis. Here, we briefly review historical approaches to therapy and present a long-term survivor in the case of an 11-year-old female with metastatic ovarian angiosarcoma. This is the second reported case to utilize heated intraperitoneal chemotherapy in the treatment of this disease. Our patient is currently alive and well 3 years after initial diagnosis, significantly longer than any reported case of advanced-stage ovarian angiosarcoma.
AbstractThere are 12 cases of ovarian angiosarcoma reported in the literature. Ten of these cases presented in advanced stages with survivals of 2-30 months. Various chemotherapy regimens have been tried on these tumors including the most recent recommendation of MAID (mesna, doxorubicin, ifosfamide, and dacarbazine) and prognosis remains poor. Our patient underwent elective right pleurodesis via video-assisted thorascopic surgery under local anesthesia for an early recurrent right pleural effusion and subsequently began MAID chemotherapy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
